Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.
Identifieur interne : 002F48 ( PubMed/Corpus ); précédent : 002F47; suivant : 002F49Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.
Auteurs : Raoul Herbrecht ; Thomas F. Patterson ; Monica A. Slavin ; Oscar Marchetti ; Johan Maertens ; Elizabeth M. Johnson ; Haran T. Schlamm ; J Peter Donnelly ; Peter G. PappasSource :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2015.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Amphotericin B, Antifungal Agents, Voriconazole.
- drug therapy : Invasive Pulmonary Aspergillosis.
- Adolescent, Adult, Aged, Child, Female, Humans, Male, Middle Aged, Prospective Studies, Survival Analysis, Treatment Outcome, Young Adult.
Abstract
Strict definition of invasive aspergillosis (IA) cases is required to allow precise conclusions about the efficacy of antifungal therapy. The Global Comparative Aspergillus Study (GCAS) compared voriconazole to amphotericin B (AmB) deoxycholate for the primary therapy of IA. Because predefined definitions used for this trial were substantially different from the consensus definitions proposed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group in 2008, we recategorized the 379 episodes of the GCAS according to the later definitions.
DOI: 10.1093/cid/ciu911
PubMed: 25414266
Links to Exploration step
pubmed:25414266Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.</title><author><name sortKey="Herbrecht, Raoul" sort="Herbrecht, Raoul" uniqKey="Herbrecht R" first="Raoul" last="Herbrecht">Raoul Herbrecht</name><affiliation><nlm:affiliation>Department of Oncology and Hematology, Hôpital de Hautepierre and Université de Strasbourg, France.</nlm:affiliation></affiliation></author><author><name sortKey="Patterson, Thomas F" sort="Patterson, Thomas F" uniqKey="Patterson T" first="Thomas F" last="Patterson">Thomas F. Patterson</name><affiliation><nlm:affiliation>University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio.</nlm:affiliation></affiliation></author><author><name sortKey="Slavin, Monica A" sort="Slavin, Monica A" uniqKey="Slavin M" first="Monica A" last="Slavin">Monica A. Slavin</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Center and University of Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Marchetti, Oscar" sort="Marchetti, Oscar" uniqKey="Marchetti O" first="Oscar" last="Marchetti">Oscar Marchetti</name><affiliation><nlm:affiliation>Infectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV), Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Maertens, Johan" sort="Maertens, Johan" uniqKey="Maertens J" first="Johan" last="Maertens">Johan Maertens</name><affiliation><nlm:affiliation>Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, KU Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Johnson, Elizabeth M" sort="Johnson, Elizabeth M" uniqKey="Johnson E" first="Elizabeth M" last="Johnson">Elizabeth M. Johnson</name><affiliation><nlm:affiliation>Public Health England Mycology Reference Laboratory and National Collection of Pathogenic Fungi, Bristol, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Schlamm, Haran T" sort="Schlamm, Haran T" uniqKey="Schlamm H" first="Haran T" last="Schlamm">Haran T. Schlamm</name><affiliation><nlm:affiliation>Pfizer Global Research and Development, New York, New York.</nlm:affiliation></affiliation></author><author><name sortKey="Donnelly, J Peter" sort="Donnelly, J Peter" uniqKey="Donnelly J" first="J Peter" last="Donnelly">J Peter Donnelly</name><affiliation><nlm:affiliation>Radboud University Medical Center, Nijmegen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Pappas, Peter G" sort="Pappas, Peter G" uniqKey="Pappas P" first="Peter G" last="Pappas">Peter G. Pappas</name><affiliation><nlm:affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25414266</idno><idno type="pmid">25414266</idno><idno type="doi">10.1093/cid/ciu911</idno><idno type="wicri:Area/PubMed/Corpus">002F48</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.</title><author><name sortKey="Herbrecht, Raoul" sort="Herbrecht, Raoul" uniqKey="Herbrecht R" first="Raoul" last="Herbrecht">Raoul Herbrecht</name><affiliation><nlm:affiliation>Department of Oncology and Hematology, Hôpital de Hautepierre and Université de Strasbourg, France.</nlm:affiliation></affiliation></author><author><name sortKey="Patterson, Thomas F" sort="Patterson, Thomas F" uniqKey="Patterson T" first="Thomas F" last="Patterson">Thomas F. Patterson</name><affiliation><nlm:affiliation>University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio.</nlm:affiliation></affiliation></author><author><name sortKey="Slavin, Monica A" sort="Slavin, Monica A" uniqKey="Slavin M" first="Monica A" last="Slavin">Monica A. Slavin</name><affiliation><nlm:affiliation>Peter MacCallum Cancer Center and University of Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Marchetti, Oscar" sort="Marchetti, Oscar" uniqKey="Marchetti O" first="Oscar" last="Marchetti">Oscar Marchetti</name><affiliation><nlm:affiliation>Infectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV), Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Maertens, Johan" sort="Maertens, Johan" uniqKey="Maertens J" first="Johan" last="Maertens">Johan Maertens</name><affiliation><nlm:affiliation>Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, KU Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Johnson, Elizabeth M" sort="Johnson, Elizabeth M" uniqKey="Johnson E" first="Elizabeth M" last="Johnson">Elizabeth M. Johnson</name><affiliation><nlm:affiliation>Public Health England Mycology Reference Laboratory and National Collection of Pathogenic Fungi, Bristol, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Schlamm, Haran T" sort="Schlamm, Haran T" uniqKey="Schlamm H" first="Haran T" last="Schlamm">Haran T. Schlamm</name><affiliation><nlm:affiliation>Pfizer Global Research and Development, New York, New York.</nlm:affiliation></affiliation></author><author><name sortKey="Donnelly, J Peter" sort="Donnelly, J Peter" uniqKey="Donnelly J" first="J Peter" last="Donnelly">J Peter Donnelly</name><affiliation><nlm:affiliation>Radboud University Medical Center, Nijmegen, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Pappas, Peter G" sort="Pappas, Peter G" uniqKey="Pappas P" first="Peter G" last="Pappas">Peter G. Pappas</name><affiliation><nlm:affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Amphotericin B (therapeutic use)</term><term>Antifungal Agents (therapeutic use)</term><term>Child</term><term>Female</term><term>Humans</term><term>Invasive Pulmonary Aspergillosis (drug therapy)</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Survival Analysis</term><term>Treatment Outcome</term><term>Voriconazole (therapeutic use)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amphotericin B</term><term>Antifungal Agents</term><term>Voriconazole</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Invasive Pulmonary Aspergillosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Child</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Survival Analysis</term><term>Treatment Outcome</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Strict definition of invasive aspergillosis (IA) cases is required to allow precise conclusions about the efficacy of antifungal therapy. The Global Comparative Aspergillus Study (GCAS) compared voriconazole to amphotericin B (AmB) deoxycholate for the primary therapy of IA. Because predefined definitions used for this trial were substantially different from the consensus definitions proposed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group in 2008, we recategorized the 379 episodes of the GCAS according to the later definitions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25414266</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>17</Day></DateCreated><DateCompleted><Year>2016</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.</ArticleTitle><Pagination><MedlinePgn>713-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciu911</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Strict definition of invasive aspergillosis (IA) cases is required to allow precise conclusions about the efficacy of antifungal therapy. The Global Comparative Aspergillus Study (GCAS) compared voriconazole to amphotericin B (AmB) deoxycholate for the primary therapy of IA. Because predefined definitions used for this trial were substantially different from the consensus definitions proposed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group in 2008, we recategorized the 379 episodes of the GCAS according to the later definitions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The objectives were to assess the impact of the current definitions on the classification of the episodes and to provide comparative efficacy for probable/proven and possible IA in patients treated with either voriconazole or AmB. In addition to original data, we integrated the results of baseline galactomannan serum levels obtained from 249 (65.7%) frozen samples. The original response assessment was accepted unchanged.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Recategorization allowed 59 proven, 178 probable, and 106 possible IA cases to be identified. A higher favorable 12-week response rate was obtained with voriconazole (54.7%) than with AmB (29.9%) (P < .0001). Survival was higher for voriconazole for mycologically documented (probable/proven) IA (70.2%) than with AmB (54.9%) (P = .010). Higher response rates were obtained in possible IA treated with voriconazole vs AmB with the same magnitude of difference (26.2%; 95% confidence interval [CI], 7.2%-45.3%) as in mycologically documented episodes (24.3%; 95% CI, 11.9%-36.7%), suggesting that possible cases are true IA.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Recategorization resulted in a better identification of the episodes and confirmed the higher efficacy of voriconazole over AmB deoxycholate in mycologically documented IA.</AbstractText><CopyrightInformation>© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herbrecht</LastName><ForeName>Raoul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Oncology and Hematology, Hôpital de Hautepierre and Université de Strasbourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Thomas F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>University of Texas Health Science Center and South Texas Veterans Health Care System, San Antonio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slavin</LastName><ForeName>Monica A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Peter MacCallum Cancer Center and University of Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchetti</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Infectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV), Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maertens</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, KU Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Public Health England Mycology Reference Laboratory and National Collection of Pathogenic Fungi, Bristol, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlamm</LastName><ForeName>Haran T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Pfizer Global Research and Development, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnelly</LastName><ForeName>J Peter</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappas</LastName><ForeName>Peter G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7XU7A7DROE</RegistryNumber><NameOfSubstance UI="D000666">Amphotericin B</NameOfSubstance></Chemical><Chemical><RegistryNumber>JFU09I87TR</RegistryNumber><NameOfSubstance UI="D065819">Voriconazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000666" MajorTopicYN="N">Amphotericin B</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055744" MajorTopicYN="N">Invasive Pulmonary Aspergillosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065819" MajorTopicYN="N">Voriconazole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">allogeneic hematopoietic stem cell transplantation</Keyword><Keyword MajorTopicYN="N">amphotericin B</Keyword><Keyword MajorTopicYN="N">neutropenia</Keyword><Keyword MajorTopicYN="N">preemptive therapy</Keyword><Keyword MajorTopicYN="N">voriconazole</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25414266</ArticleId><ArticleId IdType="pii">ciu911</ArticleId><ArticleId IdType="doi">10.1093/cid/ciu911</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002F48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25414266
|texte= Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25414266" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |